HWK 206
Alternative Names: HWK-206Latest Information Update: 30 May 2025
At a glance
- Originator WuXi Biologics
- Developer Whitehawk Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neuroendocrine tumours; Small cell lung cancer
Most Recent Events
- 07 Apr 2025 Whitehawk Therapeutics plans to initiate IND enabling activities in 2Q' 2025 (Whitehawk Therapeutics pipeline, April 2025)
- 07 Apr 2025 Whitehawk Therapeutics plans a phase I trial for Neuroendocrine tumours and Small cell lung cancer in USA (Parenteral) in mid 2026 (Whitehawk Therapeutics pipeline, April 2025)
- 19 Dec 2024 Whitehawk Therapeutics in-licenses HWK 206 from WuXi Biologics